Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Porter

Showing results (111-120 of 159) with videos related to

Pageof 16
Sort By:
Biotechnology Journal|November 11, 2021
Mechanistic discoveries and simulation-guided assay optimization of portable hormone biosensors with cell-free protein synthesisJohn Porter Hunt, Jackelyn Galiardi, Tyler J Free, et al.
European Journal of Endocrinology|October 26, 2020
Response to 'Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia'Robin Michelet, Johanna Melin, Zinnia P Parra-Guillen, et al.
European Journal of Endocrinology|July 5, 2020
Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young childrenRobin Michelet, Johanna Melin, Zinnia P Parra-Guillen, et al.
Blood Advances|October 15, 2021
Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitroZhi-Jian Liu, Emoke Deschmann, Haley E Ramsey, et al.
Anemia|August 28, 2012
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical TrialJohn Porter, Donald K Bowden, Marina Economou, et al.
Analytical Chemistry|May 24, 2013
Identification of differential protein binding affinities in an atropisomeric pharmaceutical compound by noncovalent mass spectrometry, equilibrium dialysis, and nuclear magnetic resonanceHannah J Maple, Rachel A Garlish, Ian Whitcombe, et al.
American Journal of Hematology|May 13, 2022
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year resultsYong-Rong Lai, Maria Domenica Cappellini, Yesim Aydinok, et al.
Leukemia Research|July 9, 2011
Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasiroxFlorian Nolte, Emanuele Angelucci, Photis Beris, et al.
Journal of Neurology|April 18, 2021
Neuropsychological and neuroimaging characteristics of classical superficial siderosisEdgar Chan, Yezen Sammaraiee, Gargi Banerjee, et al.
Journal of Medicinal Chemistry|December 14, 2011
Automated protein-ligand interaction screening by mass spectrometryHannah J Maple, Rachel A Garlish, Laura Rigau-Roca, et al.
Pageof 16

Showing results (111-120 of 159) with videos related to

Sort By:
Pageof 16
Biotechnology Journal|November 11, 2021
Mechanistic discoveries and simulation-guided assay optimization of portable hormone biosensors with cell-free protein synthesisJohn Porter Hunt, Jackelyn Galiardi, Tyler J Free, et al.
European Journal of Endocrinology|October 26, 2020
Response to 'Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia'Robin Michelet, Johanna Melin, Zinnia P Parra-Guillen, et al.
European Journal of Endocrinology|July 5, 2020
Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young childrenRobin Michelet, Johanna Melin, Zinnia P Parra-Guillen, et al.
Blood Advances|October 15, 2021
Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitroZhi-Jian Liu, Emoke Deschmann, Haley E Ramsey, et al.
Anemia|August 28, 2012
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical TrialJohn Porter, Donald K Bowden, Marina Economou, et al.
Analytical Chemistry|May 24, 2013
Identification of differential protein binding affinities in an atropisomeric pharmaceutical compound by noncovalent mass spectrometry, equilibrium dialysis, and nuclear magnetic resonanceHannah J Maple, Rachel A Garlish, Ian Whitcombe, et al.
American Journal of Hematology|May 13, 2022
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year resultsYong-Rong Lai, Maria Domenica Cappellini, Yesim Aydinok, et al.
Leukemia Research|July 9, 2011
Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasiroxFlorian Nolte, Emanuele Angelucci, Photis Beris, et al.
Journal of Neurology|April 18, 2021
Neuropsychological and neuroimaging characteristics of classical superficial siderosisEdgar Chan, Yezen Sammaraiee, Gargi Banerjee, et al.
Journal of Medicinal Chemistry|December 14, 2011
Automated protein-ligand interaction screening by mass spectrometryHannah J Maple, Rachel A Garlish, Laura Rigau-Roca, et al.
Pageof 16